Atom Investors’s Cytokinetics CYTK Stock Holding History

Atom Investors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Buy	+20,350	New	+$1.29M	0.1%	310
2024 Q3	–	Sell	-3,986	Closed	-$216K	–	496
2024 Q2	$216K	Buy	+3,986	New	+$241K	0.02%	418
2020 Q4	–	Sell	-103,957	Closed	-$2.25M	–	420
2020 Q3	$2.25M	Sell	103,957 -152,880	-60%	-$3.58M	0.21%	114
2020 Q2	$6.05M	Sell	256,837 -4,886	-2%	-$91.6K	0.39%	45
2020 Q1	$3.09M	Buy	261,723 +224,322	+600%	+$2.86M	0.27%	90
2019 Q4	$397K	Buy	+37,401	New	+$384K	0.03%	184

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Atom Investors's CYTK Position: Q1 2026 in Review

Atom Investors opened a new position in Cytokinetics (CYTK) in Q1 2026: 20,350 shares worth $1.34M. The stake represents 0.1% of the portfolio and ranks #310 among its holdings. This is a return to the name: Atom Investors previously reported a position in CYTK as recently as Q2 2024.

Atom Investors first reported a position in CYTK in Q4 2019 and has held it in 6 quarters since. The position peaked at $6.05M in Q2 2020. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Atom Investors held 20,350 shares of Cytokinetics worth $1.34M as of Q1 2026.
Cytokinetics was a new Atom Investors position in Q1 2026.
Cytokinetics made up 0.1% of Atom Investors's portfolio in Q1 2026, its #310 holding.
Atom Investors first reported a position in Cytokinetics in Q4 2019 and has held it in 6 quarters since.
Atom Investors's Cytokinetics position peaked at $6.05M in Q2 2020.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.